skip to the content

Avastin in combination with pemetrexed delivers promising outcomes


PointBreak: trial design

PointBreak: trial design19


PointBreak: Avastin plus pemetrexed first line until PD

  • In the ongoing PointBreak trial, patients are randomised to one of
    • first-line Avastin 15mg/kg plus carboplatin/pemetrexed followed by Avastin plus pemetrexed until PD
    • first-line Avastin, 15mg/kg every 3 weeks, plus carboplatin/paclitaxel followed by single-agent Avastin until PD.
 
  • Primary endpoint
    • OS.
  • Secondary endpoints
    • ORR
    • DCR
    • PFS
    • TTP
    • safety
    • QoL.
 

Next

Back